Article
Abstracts Highlight In Vitro and In Vivo Activity of Qualigen’s Pan-RAS inhibitor in (1) Pancreatic Cancer, and (2) Malignant Peripheral Nerve Sheath Tumors Excerpt from the Press Release: CARLSBAD, Calif., May 26, 2022 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers…
Read More
Phase 1 study evaluates safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of YL-13027, an inhibitor of TGFβ signaling Excerpt from the Press Release: SAN FRANCISCO, May 26, 2022 (GLOBE NEWSWIRE) — Yingli Pharma US, Inc, (the “Company” or “Yingli”), a clinical stage biotechnology company developing oral small molecule drugs for cancers and other diseases with…
Read More
– EGFRxCD3-targeting bispecific is sixth CytomX Probody® therapeutic candidate to enter the clinic – Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., May 26, 2022 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that the first patient has been dosed in a…
Read More
– Pharmacokinetic profile supports potential for once-daily dosing in moderate-to-severe psoriasis – – Wide range of doses explore higher ranges of TYK2 inhibition in the clinic than reported by other agents – Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nimbus Therapeutics, a clinical-stage company that is working to design and develop breakthrough medicines through its…
Read MoreLong-term data from Opdivo plus Yervoy-based combinations demonstrate durable survival in metastatic non-small cell lung cancer (NSCLC) and metastatic melanoma, including results from landmark five-year analysis of CheckMate -227 in NSCLC First disclosure from PILOT study of Breyanzi in second-line large B-cell lymphoma underscores important role of cell therapy earlier in treatment paradigm New data…
Read More
Data on Genetically Engineered Hypoimmunogenic Human Hepatocytes Demonstrate Proof of Concept in a Metabolic Liver Disease Model Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Ambys Medicines, a company pioneering cell-replacement therapies for patients with liver disease, today announced new data on its universal hepatocyte program in an oral presentation at the American Society…
Read More
Dosing of the first subject in a Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety and efficacy of SP-103 (lidocaine topical system) 5.4% in subjects with moderate to severe acute lower back pain (LBP). The trial will enroll 80 patients with acute lower back pain. SP-103 is a pharmacologically validated…
Read More
SZN-1326 is a Fzd5-targeted Wnt-mimetic (SWAP) bi-specific antibody First part of three-part Phase 1/1b trial starts in healthy volunteers Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., May 18, 2022 (GLOBE NEWSWIRE) — Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a clinical-stage company pioneering targeted therapeutics that selectively activate the Wnt pathway for…
Read More
– Oral presentation of new preclinical data at American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting – Excerpt from the Press Release: SAN DIEGO, May 19, 2022 /PRNewswire/ — Locanabio, Inc., a genetic medicines company developing RNA-targeted therapeutics for patients with severe neuromuscular and neurodegenerative diseases, today announced the presentation of new preclinical data on its…
Read More
A preclinical study in hamsters showed both a decrease in infectious virus and in transmission Phase 1 data measuring cross-reactivity also included in the publication Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., May 19, 2022 (GLOBE NEWSWIRE) — Science Translational Medicine has published the results of a Duke University-led preclinical hamster transmission study that found that…
Read More